<DOC>
	<DOCNO>NCT00940160</DOCNO>
	<brief_summary>This study design investigate safety tolerability multiple dos QAX576 control partially control asthma patient .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics QAX576 Asthma Patients</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Nonsmoking male female subject age 18 65 year , inclusive ; control partially control asthma otherwise healthy determine past medical history , physical examination , vital sign , electrocardiogram , laboratory test screen . Female subject allow participate study postmenopausal surgically sterilize . Controlled partially control asthma define GINA 2007 . At Screening , Baseline , vital sign ( systolic diastolic blood pressure pulse rate ) assess subject rest least three ( 3 ) minute . Female subject must postmenopausal confirm FSH â‰¥ 40 , surgically sterilize least 6 month prior screen . Subjects must body mass index ( BMI ) within range 18 30 kg/m2 . Male subject must use two method contraception , i.e. , spermicidal gel plus condom , entire duration study , Study Completion visit , refrain father child six ( 6 ) month study completion Exclusion criterion Smokers ( use tobacco product previous 3 month ) . Use prescription drug stable ( 4 week ) use hormone replacement thyroid replacement within four ( 4 ) week prior dose ( medication require treatment asthma ) . Use counter ( OTC ) medication within forty eight ( 48 ) hour prior dose . Use oral steroid within 12 week prior dose . Patients receive investigational drug clinical investigation within 4 week prior dose longer required local regulation , limitation participation base local regulation . Any immunotherapy systemic biologics treatment therapy clinical study last 6 month . Any immunotherapy subcutaneous injection allergy ( allergy shot ) , within 3 month . Donation loss 400 mL blood within 8 week prior first dose , longer required local regulation . Patients suffer hay fever screen likely require treatment study . History chronic respiratory disease asthma chronic allergic rhinitis . Hospitalization asthma last year . History intubation/assisted ventilation asthma last 5 year . History autonomic dysfunction ( e.g . history fainting , orthostatic hypotension ) . History presence surgical medical condition clinically significant abnormal laboratory finding , , opinion investigator , may jeopardize subject case participation study . History drug alcohol abuse within 12 month prior dose evidence abuse indicate laboratory assay conduct screen baseline evaluation . History clinical schistosomiasis travel within precede 6 month area endemic schistosomiasis , include limited Southeast Asia Northwest Africa .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Asthma</keyword>
</DOC>